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ABSTRACT: N-(4-Hydroxyphenyl)arachidonoylamide (AM404) is an inhibitor of endocannabinoid inactiva-
tion that has been used in cellular and animal studies. AM404 is a derivative of arachidonic acid and has been
reported to inhibit arachidonate oxygenation by prostaglandin endoperoxide synthase-1 and -2 (PGHS-1
and-2,respectively). WhileexaminingthestructuralrequirementsforinhibitionofPGHS, wediscoveredthat
the meta isomer of AM404, N-(3-hydroxyphenyl)arachidonoylamide (3-HPAA), is a substrate for purified
PGHS. PGHS-2 efficiently oxygenated 3-HPAA to prostaglandin and hydroxyeicosatetraenoate products.
No oxidation of the phenolamide moiety was observed. 3-HPAA appeared to be converted by PGHS-1 in a
similar manner; however, conversion was less efficient than that by PGHS-2. PGHS-2 was selectively, dose-
dependently, and irreversibly inactivated in the presence of 3-HPAA. Complete inactivation of PGHS-2 was
achievedwith10μM3-HPAA.Preliminarycharacterizationrevealedthat3-HPAAinactivationdidnotresult
from covalent modification of PGHS-2 or damage to the heme moiety. These studies provide additional
insight into the structural requirements for substrate metabolism and inactivation of PGHS and report the
first metabolism-dependent, selective inactivator of PGHS-2.
Prostaglandin endoperoxide synthase (PGHS)
1 is involved in
manyphysiologicalandpathophysiologicalfunctions.Prostaglan-
din H2(PGH2) is an end product of the PGHS reaction and serves
as the precursor for prostaglandins, prostacyclin, and thrombox-
ane, which mediate processes such as inflammation, platelet
aggregation, and cell proliferation, among others (1, 2). PGHS
catalyzes the removal of a bis-allylic hydrogen from arachidonate,
which allows sequential incorporation of two molecules of oxygen
intothefattyacidsubstratetoyieldthehydroperoxyendoperoxide,
prostaglandin G2 (PGG2) (Figure 1A). The hydroperoxide of
PGG2 is subsequently reduced at a separate peroxidase active site
of the protein to yield the hydroxyendoperoxide, PGH2.M o s t
mammals express two functional isoforms of PGHS, designated
PGHS-1 and PGHS-2 (3-5). The expression profiles and biolo-
gical functions of the isoforms differ (6), although the proteins are
homologous in sequence and structure (3-5, 7).
Structural and functional studies reveal that fatty acid sub-
strates bind to PGHS in an inverted L-shaped conformation
(Figure 1B) (8-11). This conformation is required to yield the
appropriate product stereochemistry (12). Fatty acids utilize
ionic and/or hydrogen bonding to active site residues Arg-120
and Tyr-355 to stabilize binding (9). Arg-120 is required for
high-affinity binding to PGHS-1 but not PGHS-2 (13). In
PGHS-2, the presence of valine at positions 434 and 523, which
are both occupied by isoleucine in PGHS-1, increases the active
site volume and allows ligands access to an additional hydro-
philic interaction at Arg-513 (7, 14). These key structural
differences allow PGHS-2 to metabolize a wider range of
substrates than PGHS-1 (15-17). PGHS-2-selective substrates
include the endocannabinoids 2-arachidonoylglycerol and ara-
chidonoylethanolamide, as wellas arachidonoylamides of amino
acids (glycine, alanine, and γ-aminobutyric acid). However,
PGHS-2 does not efficiently metabolize bulkier aromatic con-
jugates of arachidonate such as N-arachidonoyldopamine or its
O-desmethyl analogue.
AM404 (Figure 1C) is a phenolamide conjugate of arachidonic
acid that can be generated in vivo from acetaminophen or
p-aminophenol (18). It was first described as an inhibitor of
cellular endocannabinoid uptake (19) and has been used as an
alternative to cannabinoid receptor agonists in animal studies of
the physiology of endocannabinoids (20-22). However, AM404
acts at multiple targets. It inhibits fatty acid amide hydrolase (23),
the key enzyme regulating arachidonoylethanolamide levels, acti-
vates transient receptor potential vanilloid receptor 1 (24), and
inhibits both isoforms of PGHS (18). In an effort to understand
determinants of binding and metabolism of arachidonoylamides,
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we synthesized a small series of substituted phenylarachidonoyla-
mides. This led to the discovery that the meta isomer of AM404,
N-(3-hydroxyphenyl)arachidonoylamide (3-HPAA), is oxyge-
nated by PGHS and leads to enzyme inactivation. Thus, 3-HPAA
appears to be a mechanism-based inactivator of PGHS, with
selectivity for PGHS-2.
EXPERIMENTAL PROCEDURES
Materials. Arachidonic acid was purchased from NuChek
Preps (Elysian, MN). AM404 was purchased from Cayman
Chemical (Ann Arbor, MI). Ovine PGHS-1 was purified from
ram seminal vesicles (Oxford Biomedical Research, Oxford, MI)
by ion exchange and gel filtration, as previously described (25).
Expressionand PurificationofPGHS-2. MurinePGHS-2
containing a C-terminal 12-histidine tag was expressed in Spo-
dopterafrugiperda21insectcells(Invitrogen,Carlsbad,CA)from
recombinant baculovirus generated from the BD Baculogold
pVL1393 transfer vector (BD Biosciences, San Jose, CA). Cell
pellets were stored at -20 C until purification. Cells (approxi-
mately 30 g of wet weight) were resuspended in 10 volumes/wet
weight lysis buffer [25 mM Tris-HCl and 250 mM sucrose
(pH 8.0)] while being stirred. The pellet was collected by
centrifugation at 10000g and resuspended in the same volume
of lysis buffer. CHAPS was added dropwise to a final concentra-
tion of 1% (v/v) from an 11% stock solution, and the solution
wasstirredat4Cfor30min.Thesupernatantwascollectedafter
centrifugation at 48000g for 20 min. Imidazole was added to the
supernatant to a final concentration of 20 mM, and the super-
natant was mixed overnight at 4 Cw i t h1 0m Lo fN i N T A
Superflow resin (Qiagen, Valencia, CA) that had been equili-
brated with 25 mM Tris-HCl and 20 mM imidazole (pH 8.0)
with 0.4% CHAPS. The slurry was transferred to a gravity flow
column andwashedwith 3 columnvolumes(CV) of25 mMTris-
HCl and 20 mM imidazole (pH 8.0) with 0.4% CHAPS.
The concentration of imidazole was increased linearly from
20 to 500 mM over 30 CV. Pooled fractions were concentrated
and dialyzed overnight at 4 C against 20 mM Tris-HCl and
150 mMNaCl(pH 8.0) with0.4% CHAPS.PGHS-2 wasgreater
than 95% pure as determined by SDS-PAGE with BioSafe
Coomassiestain(Invitrogen),andthespecificactivitydetermined
by oxygen uptake assay was 14 μmol of arachidonate per minute
per milligram of protein.
Synthesis of 3-HPAA. A solution of pyridine containing
1equivof3-aminophenol(0.12mmol,13mg)wascooledto10C
and treated with 1 equiv of arachidonoylchloride (0.12 mmol,
40 mg) dissolved in pyridine. The reaction mixture was stirred at
room temperature for approximately 2 h, diluted with EtOAc,
and washed with water three times. The organic layer was dried
over magnesium sulfate, filtered, and dried in vacuo. 3-HPAA
was obtained by silica gel chromatography (1:4 EtOAc/hexanes)
as a light yellow oil (48%):
1H NMR (CDCl3) δ 0.87 (t, 3H,
J=6.8Hz,CH2), 1.30 (m,7H, 3   CH2 þ MeOH), 1.83 (quintet,
2H, J=7.5 Hz, CH2), 2.05 (quartet, 2H, J=6.8 Hz, CH2), 2.17
(quartet, 2H, J=6.8 Hz, CH2), 2.39 (t, 2H, J=7.6 Hz), 2.80
(m, 6H, 3   CH2), 5.39 (m, 8H, 8   CH), 6.48 (dd, 1H, Ja =7 . 9
Hz, Jb=1.1 Hz, ArH), 6.65 (dd, 1H, Ja=8.1 Hz, Jb=1.8 Hz,
ArH), 7.14 (t, 1H, J=8.0 Hz, ArH), 7.27 (s, 1H, NH), 7.97
(m, 1H, J=2.0 Hz, ArH); ESI-MS m/z [M þ Na
þ] 418.3.
Synthesis of PGE2-Phenolamide. To prepare a synthetic
standard of the m-phenolamide of PGE2 (PGE2-PA), 1 equiv of
PGE2 (49 μmol, 17.4 mg), 1.5 equiv of 3-aminophenol (73 μmol,
8.0mg),2.3equivofdiisopropylethylamine(114μmol, 14.7 mg),
and 2.4 equiv of O-(7-azabenzotriazol-1-yl)-N,N,N0,N0-tetra-
methyluronium hexafluorophosphate (HATU) were mixed in
anhydrous ACN overnight. PGE2-PA was purified by prepara-
tive normal phase thin layer chromatography (4:1 EtOAc/
hexanes with 0.1% acetic acid; Rf = 0.49):
1H NMR (MeOD)
δ 0.89 (t, 3H, J=6.6 Hz, CH3), 1.40 (m, 8H, 4   CH2), 1.73
(quintet, 2H, J=7.6 Hz, CH2), 2.11 (m, 4H, 2   CH2), 2.34
(m, 5H, 2   CH2 þ CH), 2.67 (dd, 1H, Ja=7.4 Hz, Jb =1 8H z ,
CH),4.03(m,2H,2  CH),5.34(m,1H,CH), 5.44(m,1H,CH),
5.59(m,2H,2 CH),6.50(d,1H,J=8.0Hz,ArH),6.92(d,1H,
J = 7.6 Hz, ArH), 7.07 (t, 1H, J = 8.0 Hz, ArH), 7.15 (s, 1H,
ArH); ESI-MS m/z [M þ H]
þ 444.2, [M þ NH4]
þ 461.2,
[M þ Na]
þ 466.2.
Synthesis of [1-
14C]-N-(3-Hydroxyphenyl)eicosa-5,8,
11,14-tetraenamide ([
14C]-3-HPAA). [1-
14C]Arachidonic
acid supplied in ethanol (American Radiolabeled Chemicals,
Inc., St. Louis, MO) was dried in vacuo. A mixture containing
1 equiv of [1-
14C]arachidonic acid (9.1 μmol, 2.79 mg), 1.5 equiv
of 3-aminophenol (13.6 μmol, 1.5 mg), 1.25 equiv of HATU
(11.4 μmol, 4.3 mg), and 3 equiv of triethylamine (27.3 μmol,
2.7 mg) was dissolved in anhydrous ACN and allowed to react
overnight. Separation of the reaction mixture was achieved on
system C on an Agilent Zorbax Rx-SIL column (0.46 cm  
25 cm, 5 μm). The mobile phase consisted of IPA and cyclohex-
ane. The flow rate was held constant at 1 mL/min. The IPA
concentration was held at 5% for 5 min, increased to 50% over
1 min, and held at 50% for 7 min prior to reequilibration.
Analytes were detected by UV absorption at 245 and 280 nm
and by β-RAM. Under these conditions, [
14C]-3-HPAA eluted
at 4.6 min. After reaction for 19 h, approximately 70%
[1-
14C]arachidonic acid had been converted to [
14C]-3-HPAA
FIGURE 1: (A) Conversion of arachidonoyl-derived substrates by
PGHS. Two molecules of molecular oxygen are incorporated at the
oxygenase site of PGHS to yield PGG2. In vitro, the peroxidase of
PGHS reduces the hydroperoxide to form PGH2.P G H S - 2c a t a l y z e s
identical reactions with 2-arachidonoylglycerol and arachidonoy-
lethanolamide. (B) Structure of arachidonic acid in its productive
conformationboundtoPGHS-1.Arachidonate(ballandstick)binds
to PGHS in an inverted L-shaped conformation, positioning the
pro-S hydrogen at C-13 for abstraction by Tyr-385. The carboxylate
binds at the constriction site created by Arg-120, Tyr-355, and
Glu-524. Substitutions at residues 434, 513, and 523 allow PGHS-2
to bind and oxygenate acyl amides and esters of arachidonate.
(C) Chemical structures of arachidonoylphenolamides.Article Biochemistry, Vol. 48, No. 51, 2009 12235
and an additional 10% had been converted to a secondary
product. The reaction mixture was dried in vacuo and resus-
pended in 5% isopropanol (IPA) in cyclohexane with heating.
[
14C]-3-HPAA was purified by normal phase liquid chromatog-
raphy (LC) as described on system C (see below), bypassing the
β-RAM. Fractions were pooled and dried in vacuo, resuspended
inethanol,and storedat-20C.The final product was obtained
in20%yieldat>99%puritybyUVdetectionat245and280nm
and by β-RAM detection.
Kinetics of 3-HPAA Oxidation by PGHS. The metabo-
lism of substrates was characterized by oxygen uptake as
previously described (26). To determine Michaelis-Menten
kinetic parameters, the concentration of substrate was varied
(1 to 50 μM), and rates of metabolism were determined by an O2
uptake assay. Maximal rates were converted from volts per
second to micromolar O2 per second using the calibration
constant determined by ferricyanide-catalyzed oxidation of phe-
nylhydrazine (27). Converted rates were plotted versus substrate
concentration and fit by nonlinear regression (Prism 4.0, Graph-
Pad Software, San Diego, CA) to determine vmax and Km.
EnzymeInactivationfollowing3-HPAAMetabolism.To
characterize the extent of enzyme inactivation associated with
3-HPAA metabolism, PGHS-1 or PGHS-2 was incubated with
25 μM 3-HPAA. When oxygen uptake was complete, arachido-
nic acid (25 μM) was added, and the maximal rate was deter-
mined as described above and normalized to the DMSO control.
The concentration dependence of PGHS-2 inactivation was
analyzed in a similar manner with varying concentrations of
3-HPAA (from 10 nM to 25 μM).
Reversibility of 3-HPAA-Dependent Inactivation of
PGHS. PGHS (7.5 μM) was reconstituted with 2.5 equiv of
heme in reaction buffer. Reconstituted protein was incubated
with DMSO or 1.5 mM 3-HPAA at 37 C for 90 s and then
cooled to 4 C. Aliquots were assayed for activity using the
oxygen uptake system. Remaining samples were transferred to
centrifugal filter devices (molecular mass cutoff of 30000 kDa),
and excess inhibitor was removed by three successive buffer
exchanges.Followingbuffer exchange, an additional 2.5equivof
heme was added to the protein, and aliquots of each sample were
again assayed by oxygen uptake. Activity was normalized to the
DMSO control.
Liquid Chromatography. Multiple LC systems and condi-
tions were utilized, dependent upon the application. The systems
and chromatography conditions are described here. System A
consisted of a Waters 717plus autosampler and a Waters 1525
binary HPLC pump in linewith a Waters 2996 photodiodearray
detector. System B consisted of a Waters Alliance 2695 separa-
tion module equipped with a Waters 2487 dual-wavelength
absorbance detector and a Sedere Sedex 75 evaporative light
scattering detector.System C consisted of a WatersAlliance 2695
separationmoduleequippedwithaWaters2487dual-wavelength
absorbance detector and an IN/US Systems β-RAM Flow-
Through System Model 2 radiochemical detector. For system
C, 100% of the eluent flow was diverted to the β-RAM where it
was mixed with 2 volumes of In-Flow 2:1 universal liquid
scintillator; the dwell time was 0.4 s.
Characterization of PGHS-2 Oxygenation Products of
3-HPAA. Murine PGHS-2 (200 nM) was reconstituted with
2 equiv of heme in 1 mL of reaction buffer at 37 C for 3 min.
Following reconstitution, 3-HPAA was added tothe protein toa
final concentration of 25 μM, and the reaction was allowed to
proceed for 10 min at 37 C. The reaction was quenched by the
addition of ethyl acetate containing 0.5% acetic acid and 25 μM
N-(3-methoxyphenyl)arachidonylamide as an internal standard
(IS). The organic layer was removed and dried under argon gas.
The resultant residue was suspended in an acetonitrile/water
mixture(1:3).Productswereseparated on aLunaC18(2) column
(10.0cm 0.2cm,3μm) usingsystemAorsystemB.Themobile
phase consisted of aqueous 0.5% acetic acid (A) and 0.5% acetic
acid in acetonitrile (B). Separation was performed with a flow
rateof0.3mL/min, holding at40% B for 2min before increasing
to 100% B over 30 min. The flow was held at 100% B for 15 min
prior to a return to starting conditions.
LC-MS and LC-MS/MS were performed using similar
conditions on a Waters Alliance 2690 Separation Module
coupled to a Thermofinnigan TSQ7000 triple-quadrupole mass
spectrometer. Separation was performed with a flow rate of
0.25 mL/min, holding at 40% B for 2 min before increasing to
100% B over 20 min. The flow was held at 100% B for 10 min
prior to a return to starting conditions. The instrument was
operated in positive ion mode using electrospray ionization with
a spray voltage of 4.5 kV and a capillary temperature of 225 C.
Full scan analysis was performed from m/z 350.00 to 550.00 with
a scan rate of 0.5. Ions of interest were selected for CID using a
collision energy of -15 eV.
For silver ion coordination ion spray MS (Ag
þCIS-MS) and
MS/MS, LC was conducted on a Surveyor Separation Module
using a Luna C18(2) column (10.0 cm   0.2 cm, 3 μm). The
mobile phase consisted of aqueous 80 μM silver acetate (A) and
80 μM silver acetate in methanol. Separation was performed at a
flow rate of 0.25 mL/min, holding at 75% B for 1 min before
increasing to 100% B over 15 min. The flow was held at 100% B
for 5 min prior to a return to starting conditions. The instrument
was operated in positive ion mode using electrospray ionization
with a spray voltage of 3 kV and a capillary temperature of
225 C. Full scan analysis was performed from m/z 400.00 to
600.00 with a scan rate of 1.0. Ions of interest were selected for
CID using a collision energy of -30 eV.
Characterization of PGHS-1 Oxygenation Products of
3-HPAA. Ovine PGHS-1 (500 nM) was reconstituted with
2 equiv of heme in 2.5 mL of reaction buffer at 37 C, and
reactions were conducted and samples analyzed by LC-MS as
described for PGHS-2. Tween 20, a component of PGHS-1
purification, caused ion suppression, which prevented direct
detection of 3-HPAA product molecular ions in full scan mode.
Ions of products identified in PGHS-2 samples were selected for
CID in PGHS-1 samples using a collision energy of -15 eV.
Ovine PGHS-1 (500 nM) or murine PGHS-2 (50 nM) was
reconstituted with 2 equiv of heme in a 200 μL reaction mixture
and incubated with 25 μM[
14C]-3-HPAA for 10 min at 37 C.
Reactions were quenched by the addition of ethyl acetate
containing 0.5% acetic acid. Aliquots of the organic layer were
spotted on a normal phase thin layer chromatography plate and
developed in a mobile phase that was a 75:25:1 ethyl acetate/
methylene chloride/acetic acid mixture at 4 C. These conditions
have been previously reported for the separation of arachidonic
acid and its products of oxidation by PGHS (28). Radiolabeled
products and unreacted 3-HPAA were quantified with a radio-
activity scanner (Bioscan Inc., Washington, DC). The plate was
then exposed to a phosphor screen for approximately 85 h prior
toimagingwithaBio-Rad(Hercules,CA)MolecularImagerFX.
Assessment of Covalent Modification of PGHS-2 by
3-HPAA. Covalent modification of PGHS-2 was assessed by
adaptationofapreviouslyreportedmethod(29).ApoPGHS-2or12236 Biochemistry, Vol. 48, No. 51, 2009 Turman et al.
PGHS-2with0.5 equiv of hematin (holoPGHS-2) was incubated
with 2 or 5 equiv of [
14C]-3-HPAA in 100 mM Tris-HCl (pH 8.0)
at room temperature. After incubation with [
14C]-3-HPAA for
5 min, samples were placed on ice to slow the reaction. LC
was achieved on system C with a Vydac Protein C4 column
(25.0 cm   0.46 cm, 5 μm) equipped with a widebore C4 security
guard cartridge. The mobile phase was a 9:1 H2O/ACN mixture
with 0.1% trifluoroacetic acid (A) or a 1:9 H2O/ACN mixture
with0.1%trifluoroaceticacid(B).Separationwasperformedata
flow rate of 1 mL/min, holding at 40% B for 4 min before
increasingto60%Bover30min.Theflowwasheldat60%Bfor
5 min prior to a return to starting conditions. Protein was
detected by absorbance at 280 nm and eluted at 24.4 min. Heme
was detected by absorbance at 405 nm and eluted at 6.8 min.
[
14C]-3-HPAA was detected by absorbance at 280 nm and by
radiochemical detection and eluted at 32.2 min.
Assessment of Heme Modification by 3-HPAA. Incuba-
tionsweresetupandseparatedasdescribedaboveforassessment
of covalent modification of PGHS-2, with the exception that
unlabeled 3-HPAA was used in place of [
14C]-3-HPAA, and
separationwasconductedonsystemAtoallowmonitoringofthe
heme absorbance spectrum.
RESULTS
Metabolismof3-HPAAbyPGHS. Whileinvestigatingthe
inhibitionofPGHSbyAM404analoguesusinganoxygenuptake
assay, we observed no oxygen consumption upon addition
of AM404 (up to 50 μM) to PGHS-1 or PGHS-2. In contrast,
3-HPAAwasoxygenatedbybothPGHS-1andPGHS-2.Therate
of oxygen uptake was measured at various concentrations of
3-HPAA and arachidonic acid, and the Michaelis-Menten
kinetic parameters were determined (Table 1 and Figure 2).
Oxygen uptake rates at 3-HPAA concentrations above 50 μM
were not reproducible due to the limited solubility of the
compound. The overall efficiency of 3-HPAA metabolism by
PGHS-1 was approximately 10-fold lower than that of arachi-
donic acid, as evidenced by kcat/Km. The resulting efficiency for
3-HPAAmetabolismbyPGHS-2wasreducedbylessthan3-fold.
The kcat values for the two substrates were comparable for
PGHS-2, but the Km for 3-HPAA was higher. In contrast to
arachidonate, oxygenation of 3-HPAA by PGHS-2 was signifi-
cantly inhibited at high substrate concentrations.
Characterization of Products of 3-HPAA Oxidation by
PGHS-2. Following incubations of PGHS-2 with 3-HPAA,
mixtureswereextracted,separatedbyHPLC,andanalyzedusing
eitheradiodearraydetectororatriple-quadrupolemassspectro-
meter. Eluting components were detected by absorbance at
245 nm, a wavelength characteristic of the phenolamide moiety
(Figure 3). No additional products could be detected via
evaporative light scattering detection or mass spectrometry.
Labeled peaks were not observed in controls lacking either
3-HPA or protein.
UV spectra of products 1-4 closely resemble those of 3-HPA
(Figure4andFigureS1oftheSupportingInformation). Product
1 was not sufficiently resolved via LC-MS to gather mass
spectrometric data. Products 2-4 exhibited similar mass spectra,
with m/z values of 466, 461, 444, 426, and 408 as major ions
(Figure 5A and Figures S2 and S3A of the Supporting In-
formation). [M þ H]
þ (m/z 444) corresponds to the incorpora-
tion of three atoms of oxygen, consistent with a prostaglandin
(PG)-derived species. This was supported by Ag
þCIS-MS, in
which the major ions observed were at m/z 550 and 552 (Figure
S4 of the Supporting Information); these were the predicted ions
for a PG-derived species coordinated with
107Ag
þ and
109Ag
þ,
the most abundant naturally occurring isotopes. Under standard
LC-MS conditions, other ions present in the spectra represent
the ammonium and sodium adducts, m/z 461 and 466, respec-
tively,aswellastheneutrallossofoneortwowaters,m/z426and
408 (Figure 5A). Further characterization of products 2 and
4 was achieved by collision-induced dissociation (CID) of m/z
444; due tothe low abundance of m/z 444 for product 3, CID did
not provide a sufficient signal-to-noise ratio for resolution of
specific fragment ions. CID of products 2 and 4 yielded similar
fragments, the most prevalent being m/z 426, 408, 317, and 299
(Figure 5B and Figure S3B of the Supporting Information). The
Table 1: Michaelis-Menten Kinetic Parameters for Oxygenation of
Arachidonic Acid (AA) and 3-HPAA by PGHS
a
PGHS-1 PGHS-2
AA 3-HPAA AA 3-HPAA
kcat (s
-1)5 1 ( 32 2 ( 14 7 ( 24 8 ( 3
Km (μM) 3.4 ( 0.6 15 ( 12 . 5 ( 0.4 6 ( 1
kcat/Km (s
-1 μM
-1)1 5 ( 1 1.5 ( 11 9 ( 17 ( 2
aParameters ( the standard deviation were determined by nonlinear
regression of data shown in Figure 2.
FIGURE 2: Concentration dependence of maximal rates of arachido-
nate (9) and 3-HPAA (0) oxygenation by (A) PGHS-1 and (B)
PGHS-2. Each point represents the mean ( standard deviation of
three independent measurements. Kinetic parameters were deter-
mined by nonlinear regression and are reported in Table 1. The
dashed line in panel B represents the fit predicted in the absence of
substrate inhibition.Article Biochemistry, Vol. 48, No. 51, 2009 12237
full scan Q1 and CID spectra are consistent with PGE2/D2-PA,
nonenzymatic degradation products of PGH2-PA (Figure 5C).
An authentic standard of PGE2-PA was synthesized; the HPLC
retention time andfullscan Q1andCIDspectrawereidenticalto
those of product 2 (Figure S5 of the Supporting Information),
supporting the hypothesis that this product is PGE2-PA. PGD2
differs from PGE2 only in the position of the carbonyl and
hydroxyl on the cyclopentane ring, and CID fragmentation
patterns of the isomers are indistinguishable. On reversed phase
chromatography systems, PGE2 elutes before PGD2, and this
elution order is maintained for the glyceryl esters and ethanola-
mides (unpublished observations). Thus, product 4 likely repre-
sentsPGD2-PA.Product5exhibitsionsatm/z394, 389, and 354,
which may represent adducts of sodium and ammonium and the
neutral loss of water from 12-hydroxyheptadecatrienoylpheno-
lamide (HHT-PA),which results fromthe lossof malonaldehyde
from PGH2-PA (Figure 6). CID of the ion at m/z 389 yields ions
at m/z 372 (the presumed [M þ H]
þ), 354 (neutral loss of water),
and 244 (loss of aminophenol and water). Taken together,
analysis of products 2-5 strongly supports the hypothesis that
PGHS-2 produces PG-like products from 3-HPAA.
Products 6 and 7 represent a distinct class of oxygenation
products assigned as hydroxyeicosatetranoyl-phenolamides
(HETE-PAs). Both products absorbed strongly at 236 nm,
FIGURE 3: Chromatographic profile of products of PGHS-2-dependent oxygenation of 3-HPAA. (A) Following incubation of PGHS-2 with
3-HPAA, products were separated by reverse phase chromatography (elution gradient on the right axis) and eluting products detected via
absorbanceat245nm.ExpandedviewsofthetwomajorsetsofproductsareshowninpanelsBandC.Labeledpeakswerenotobservedinblank
reaction mixtures lacking either PGHS-2 or 3-HPAA. IS denotes internal standard.
FIGURE 4: UV profiles of 3-HPAA and two products of 3-HPAA
oxygenation by PGHS-2. Peak numbers correspond to assignments
made in Figure 3. UV profiles of all products of 3-HPAA oxygena-
tion are provided in Figure S1 of the Supporting Information.
FIGURE 5: Mass spectral characterization and proposed structure of
a prostaglandin-like product formed by oxygenation of 3-HPAA by
PGHS-2.(A)FullscanMSofpeak2.(B)CIDoftheionatm/z444at
peak2.(C)Proposedstructureandfragmentationofproduct2.Loss
of hydroxyl groups (17 mu) is observed via CID as a neutral loss of
water (18 mu). The structure shown is that of PGE2-PA.12238 Biochemistry, Vol. 48, No. 51, 2009 Turman et al.
characteristic of a conjugated diene system (Figure 4). Full
scan Q1 spectra of both products exhibited an ion at m/z 394
(Figure7A).Thisislikelyaresultoftheneutrallossofwaterfrom
the [M þ H]
þ species of HETE-PA, which would have an ion
at m/z 412. Small amounts of ions at m/z 434 and 429 were
observed, corresponding to the sodiated and ammoniated mole-
cular ions. Using Ag
þCIS-MS, ions at m/z 518 and 520 were
observed at approximately equal intensities, consistent with
107Ag
þ and
109Ag
þ adducts of a mono-oxygenated product of
3-HPAA (Figure S6A of the Supporting Information). CID of
the presumed ammonium adduct of product 7 (m/z 429) yielded
fragments corresponding to the loss of water and aminophenol
(Figure 7B). However, the signal:noise ratio in the resulting CID
spectrum was insufficient to permit assignment of the position of
oxygenation. Ag
þCIS-MS/MS of the ion at m/z 518 revealed
distinctfragmentationpatternsforproducts6and7(FigureS6B,
CoftheSupportingInformation).Onthebasisofthemechanism
of arachidonic acid metabolism by PGHS-2 and fragmentation
observed by Ag
þCIS-MS/MS, it is hypothesized that products
6 and 7 represent 15- and 11-HETE-PA, respectively.
Characterization of Products of 3-HPAA Oxidation by
PGHS-1. The products of 3-HPAA oxidation by PGHS-1 were
analyzed by LC-MS in positive ion mode. However, Tween 20,
the detergent used in purification of PGHS-1, caused ion
suppression in full scan mode (Figures S7 and S8 of the
Supporting Information). CID was conducted for ions at m/z
444, 389, and 429, the ions of interest identified from PGHS-2
samples. This allowed detection of products in PGHS-1 samples
withretentiontimesandCIDspectrasimilartothoseofproducts
2[ P G E 2-PA (Figure S9 of the Supporting Information)] and
5 [HHT-PA (Figure S10 of the Supporting Information)] in
PGHS-2samples.Inaddition,PGHSwasincubatedwith[
14C]-3-
HPAA, and the product profiles were compared by TLC. With
PGHS-1, the observed products comigrated with PGHS-2 pro-
ducts(Figure8).Quantificationsuggestedthatthedistributionof
products was similar for PGHS-1 and PGHS-2 (Table S1 of the
SupportingInformation).However,toachieveasimilarextentof
3-HPAAmetabolism,theconcentrationofPGHS-1requiredwas
10-fold higher than that of PGHS-2. The data indicate that
FIGURE 6: Mass spectral characterization and proposed structure of
an HHT-like product formed following oxygenation of 3-HPAA by
PGHS-2.(A)FullscanMSofpeak5.(B)CIDoftheionatm/z389at
peak 5, the ammoniated adduct of the ion at m/z 372. (C) Proposed
structureandfragmentationofproduct5.Lossofthehydroxylgroup
(17 mu) is observed via CID as a neutral loss of water (18 mu).
FIGURE 7: Mass spectral characterization and proposed representa-
tivestructureofaHETE-likeproductformedfollowingoxygenation
of 3-HPAA by PGHS-2. (A) Full scan MS of peak 7. (B) CID of
the ion at m/z 429 at peak 7, the ammoniated adduct of the ion at
m/z 412. (C) Proposed representative structure and fragmentation of
product7.Lossofthehydroxylgroup(17mu)isobservedviaCIDas
aneutrallossofwater(18mu).Fragmentsconsistentwithaproposed
structure of 11-HETE-PA were detected using Ag
þCIS-MS/MS
(Figure S6B of the Supporting Information).
FIGURE 8: Oxygenation of [
14C]-3-HPAA by PGHS. [
14C]-3-HPAA
was incubated in buffer alone or with 500 nM PGHS-1 or 50 nM
PGHS-2. Products were analyzed by thin layer chromatography.
Spots (indicated by arrows) that were not in controls lacking protein
but were observed in PGHS-1 samples comigrate with PGHS-2
products. Radiometric quantification of products is shown in Table
S1 of the Supporting Information.Article Biochemistry, Vol. 48, No. 51, 2009 12239
PGHS-1converts3-HPAAtoproductssimilartoPGHS-2,albeit
less efficiently.
InactivationofPGHSby3-HPAA.Athighconcentrations
of 3-HPAA, the rate of 3-HPAA oxygenation by PGHS-2 was
drastically reduced (Figure 2), suggesting the enzyme might be
undergoing inactivation. Therefore, the ability of 3-HPAA to
inhibit oxidation of arachidonate by PGHS was examined.
Following metabolism of 25 μM 3-HPAA, PGHS-1 showed an
only 30% reduction in its ability to oxidize arachidonic acid.
Because of the low solubility of 3-HPAA at higher concentra-
tions, an IC50 for PGHS-1 could not be determined. However,
under the same conditions, PGHS-2 was completely inactivated
(Figure 9).
To determine the IC50, the concentration of 3-HPAA required
to inhibit activity by 50%, PGHS-2 was incubated with 3-HPAA
untiloxygenuptakewascompleteorfor30s,ifoxygenuptakewas
undetectable. Following the preincubation with 3-HPAA, 25 μM
arachidonic acid was added, and the rate of oxygenation was
determined and normalized to the DMSO control (Figure 10). An
IC50 of 1.6 μM was determined with complete inactivation
occurring at g10 μM. At concentrations of <1 μM, turnover of
3-HPAA was undetectable; at these same concentrations, arachi-
donic acid metabolism was minimally inhibited. However, sig-
nificantinactivationofPGHS-2wasobservedatconcentrationsof
3-HPAA corresponding to observable metabolism of 3-HPAA,
whereas complete inactivation of PGHS-1 could not be achieved.
To determine if the inactivation of PGHS-2 by 3-HPAA was
reversible, holo-PGHS-2 was incubated with 10 μM 3-HPAA, a
concentrationof3-HPAAatwhichnoresidualenzymaticactivity
remained. Following incubation with 3-HPAA or vehicle, the
protein sample was subjected to ultrafiltration to remove excess
inhibitor and analyzed for its ability to metabolize arachidonic
acid (Figure S11 of the Supporting Information). The sample
treated with 3-HPAA did not metabolize arachidonic acid
following ultrafiltration, indicating that inactivation of PGHS-
2 by 3-HPAA was irreversible.
Assessment of PGHS-2 Protein and Heme Modification
by 3-HPAA. Inactivation of PGHS-2 by 3-HPAA could
potentially be mediated by damage to the heme moiety of
PGHS-2 or modification of the protein. Following incubation
of PGHS-2 with [
14C]-3-HPAA, protein samples were analyzed
by HPLC with UV and radiochemical detection. Radioactivity
did not coelute with either protein or heme, indicating that
3-HPAA did not covalently modify the protein or the heme
(Figure S12 of the Supporting Information). PGHS-2 also was
incubated with unlabeled 3-HPAA, and samples were analyzed
using LC with a photodiode array detector to allow monitoring
of the heme spectrum. No change in the retention time or the
hemespectrumwas noted,indicatingthat3-HPAAdid notcause
oxidative damage to the heme or cross-linking of heme to the
protein (Figure S13 of the Supporting Information).
DISCUSSION
OxidationofarachidonicacidbyPGHSiscriticalinnumerous
physiological and pathophysiological states (1, 2). The growing
list of substrates that can be metabolized by PGHS, often
selectively by PGHS-2, highlights the importance of characteriz-
ing the interaction of fatty acid-derived molecules with lipid
dioxygenases, particularly when such compounds, including
AM404, are utilized in vivo to study the biology of complex
signaling networks. The interactions of N-(hydroxyphenyl)-
arachidonoylamides with PGHS provide an interesting exa-
mple of how subtle structural perturbations can significantly
impact the binding of small molecule to their targets. The
paraisomer (AM404) acts as an inhibitor of PGHS (18),whereas
we report here that the meta isomer serves as a substrate for
PGHS.
3-HPAA is more efficiently metabolized by PGHS-2 than
PGHS-1, as observed with many other arachidonoyl amides
and esters. For PGHS-2, kcat is identical for arachidonate and
3-HPAA.ThehigherKMfor3-HPAAaccountsfordifferencesin
the catalytic efficiency (kcat/KM) for 3-HPAA and arachidonate.
The efficiency of 3-HPAA oxygenation by PGHS-2 is somewhat
surprising, as N-arachidonoyldopamine and its O-desmethyl
analogue are poor substrates for this enzyme (30). PGHS-2
produces phenolamide derivatives of prostaglandins and HETEs
from 3-HPAA. The same classes of products are observed
for arachidonic acid and 2-arachidonoylglycerol, suggesting
3-HPAA adopts a conformation similar to that of other arachi-
donoyl derivatives. Although PGHS-1 oxidizes 3-HPAA much
FIGURE 9: Oxygenation of 3-HPAA by PGHS-1 and PGHS-2 and
subsequent oxygenation of arachidonic acid. Upon addition of
25 μM 3-HPAA to PGHS-1 (A) or PGHS-2 (B), oxygen in solution
was consumed, indicating metabolism of 3-HPAA. Once oxygena-
tion of 3-HPAA had proceeded to completion, 25 μM arachidonic
acid(AA)wasadded.PGHS-1couldstillmetabolizearachidonate,as
evidenced by oxygen consumption, but PGHS-2 was completely
inactivated.ControlcurvesforoxygenationofAAfollowingincuba-
tion with vehicle are also shown for PGHS-1 (C) and PGHS-2 (D).
FIGURE 10: Concentration dependence of PGHS-2 inactivation by
3-HPAA. PGHS-2 was incubated with various concentrations of
3-HPAA. Once oxygenation of 3-HPAA had proceeded to comple-
tion, arachidonic acid (25 μM) was added. The maximal rate of
oxygen uptake was determined and normalized to vehicle control.
Each point represents the mean ( standard deviation of three
independent measurements.12240 Biochemistry, Vol. 48, No. 51, 2009 Turman et al.
lessefficiently thanPGHS-2,PGHS-1seems toproduce a similar
product profile.
Following metabolism of 3-HPAA, oxygenase activity
is reduced in both PGHS-1 and PGHS-2. PGHS-1 activity is
reduced by only 30% at 25 μM 3-HPAA, whereas PGHS-2 is
completely and irreversibly inactivated. Metabolism of 3-HPAA
does not seem to result in covalent modification, oxidation, or
cross-linking ofthe heme moiety. Inaddition,covalent modifica-
tionofPGHS-2proteinwasnotdetectable.Thisbehaviorisquite
similar to substrate-dependent autoinactivation of PGHS, which
isobserved witharachidonate and othersubstrates.The mechan-
ismofPGHSautoinactivationremainselusive.Aswith3-HPAA,
inactivation during arachidonate turnover is not associated
with heme inactivation (31, 32). Covalent modification of PGHS
has been observed following metabolism of arachidonate, but
this occurs on a time scale slower than that of autoinacti-
vation (33-35). A favored model of autoinactivation suggests
that a critical residue such as the catalytic tyrosine, Tyr-385, is
damaged during the course of catalysis. Oxidative damage to
PGHS may provide a mechanism for inactivation of PGHS by
3-HPAAaswell.Oxidationofsidechainshasnotpreviouslybeen
reported for PGHS, although this may be due to inadequate
technology for assessing such modifications, which would pro-
duce a mass shift of only 1, 2, or 16 mass units.
N-(Hydroxyphenyl)arachidonoylamides provide a unique ser-
iesforelucidatingdeterminantsofbindingofligandstoPGHS.A
definitive switch from inhibitor to substrate is noted by moving
the hydroxyl group from the para to the meta position on the
phenyl ring. This suggests that 3-HPAA adopts a distinct
conformation that permits it to be oxygenated by PGHS. Future
structural studies of the para and meta isomers bound to PGHS
could provide unique insights into the structural determinants of
ligand binding and metabolism.
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